Designing Longevity
Skip to main content

Headaches and Migraine

A headache that comes on suddenly and severely, or comes with new trouble speaking, weakness or confusion, needs emergency assessment. For recurring headaches, a short diary helps a clinician identify the pattern and discuss a plan for both attacks and prevention.

Sources reviewed November 13, 2026 · How we work

Recognize emergency headache signs

Call 911 in the U.S. for a sudden, explosive headache or a headache with new weakness, slurred speech or confusion. A severe headache after a head injury or with fever and a stiff neck also needs emergency assessment.

Arrange a medical visit when the headache pattern changes, headaches recur or they interfere with work, school or other daily activities.

Sources for this section

Bring a headache diary to the visit

Record the date, how long the pain lasted, where it hurt, and whether nausea, light sensitivity or visual changes came with it. Include the medicines you took, whether they helped and what activities you missed. Count headache days and days you used a medicine for relief.

Recurring headache can have several causes. Exam findings and the pattern help a clinician distinguish migraine from other headache types. Some people with migraine experience aura, such as flashing lights or other temporary changes in vision, before or during an attack. New stroke-like symptoms still need emergency assessment.

Sources for this section

Treating a migraine attack

An attack plan addresses what to do when a migraine starts. Depending on the diagnosis and health history, a clinician may discuss over-the-counter pain relievers, triptans or newer medicines called gepants. Ubrelvy (ubrogepant) 100 mg, sold in a prescription carton of 10 tablets, is one labeled example for adults with migraine with or without aura.

Frequent use of some headache medicines can make headache harder to manage. The number of days you use relief medicine and how well it works can help a clinician decide whether to discuss prevention.

Sources for this section

Talking through a migraine prevention plan

Prevention aims to reduce the number or impact of future attacks. A clinician can compare medicines such as certain beta-blockers, anti-seizure medicines and drugs that target CGRP, which stands for calcitonin gene-related peptide. The American Headache Society considers CGRP-targeting prevention a first-line option alongside other established choices.

CGRP is a signaling peptide involved in migraine. Some prescription antibodies bind CGRP itself or its receptor. Gepants are smaller drugs that block the receptor. Approved uses vary by product, including prevention for some medicines and treatment during an attack for others.

At an initial visit, ask how you will track progress and when you will review side effects, headache days and impact on daily life. Before filling a prescription, check whether your plan covers the exact medicine and whether it requires prior authorization, meaning insurer approval before coverage. If you need specialist care, ask about referral requirements and who will manage follow-up.

Sources for this section

Compare how often and where you take each medicine

If you want fewer treatment days at home, the FDA-approved Ajovy quarterly schedule uses three injections on the same day every three months. If you prefer a health professional to give the medicine, Vyepti is an infusion into a vein every three months.

Other home options include monthly Emgality and Aimovig pens, a daily Qulipta tablet, and an every-other-day Nurtec ODT tablet for episodic migraine prevention. Compare time and travel, how comfortable you are with injections, and your costs under the actual pharmacy or medical benefit. Ask your clinician which of the options fits your health history.

Our picks for specific needs

An upfront cash quote for continuing migraine prevention

Emgality through LillyDirect

CGRP antibody · U.S. cash-pay program · one 120 mg/mL prefilled pen · NDC 0002-1436-11

FDA-approved prescription medicine

LillyDirect advertises a starting price of $299 per month for eligible adults filling a continuing migraine-prevention prescription.

This quote covers the continuing one-pen prescription before applicable taxes or fees. The starting dose and clinician care have separate costs. Cash payments under this program do not count toward insurance deductibles.

See the labeled Emgality pen and trial results

Sources checked (U.S. Eastern time)

Sources for this section

Ajovy for fewer injection days at home

The quarterly option for adults uses a carton of three 225 mg/1.5 mL single-dose autoinjectors, drug package code (NDC) 51759-202-22. Adults can self-inject after training. The labeled monthly schedule uses one injection. Discuss which schedule fits your prescription and check the cost of the exact three-pen fill. The 2026 manufacturer’s savings card is for eligible commercial pharmacy coverage and excludes cash-pay and uninsured fills.

Injection-site reactions are common. The label also warns about serious allergic reactions, constipation with serious complications, high blood pressure and Raynaud’s phenomenon, which can reduce blood flow to fingers and toes.

Sources for this section

Vyepti for a quarterly infusion from a health professional

The 100 mg/mL single-dose vial, NDC 67386-130-51, is used for an infusion into a vein. A health professional gives the recommended 100 mg infusion over about 30 minutes every three months. The label also allows 300 mg for some patients. Ask how long the full visit takes and whether your medical plan covers the medicine and administration at the same location.

The label warns about allergic reactions, constipation with serious complications, high blood pressure and Raynaud’s phenomenon. Ask the infusion site for separate medicine and administration estimates before scheduling.

Sources for this section

Emgality pen for adult migraine prevention

The 120 mg/mL single-dose pen contains galcanezumab, an antibody that binds CGRP. The U.S. label lists both one- and two-pen cartons. The label describes an initial loading dose followed by monthly injections. Warnings include serious allergic reactions, constipation with serious complications, high blood pressure and Raynaud’s phenomenon.

In a three-month trial in adults with chronic migraine, people in the 120 mg monthly group averaged 4.8 fewer migraine headache days per month than they had at the start. The placebo group averaged 2.7 fewer days. That trial compared Emgality with placebo.

Sources for this section

Aimovig monthly pen for adult migraine prevention

Erenumab is an antibody that targets the CGRP receptor. Aimovig’s label lists single-dose 70 mg/mL and 140 mg/mL autoinjectors. Verify the product and strength on the prescription, whether your plan requires prior approval and the cost for that exact fill.

The label lists injection-site reactions and constipation among the most common adverse reactions. Its warnings include serious allergic reactions, constipation complications, high blood pressure and Raynaud’s phenomenon.

Sources for this section

Qulipta tablets for adult migraine prevention

The U.S. label includes a 30-count bottle of 60 mg atogepant tablets. Atogepant is an oral gepant taken daily for prevention. The label lists nausea, constipation and tiredness or sleepiness among common side effects. Other medicines and kidney function can affect which dose is appropriate.

In a separate 12-week trial in adults with chronic migraine, people in the 60 mg group averaged 6.9 fewer migraine days per month than they had at the start. The placebo group averaged 5.1 fewer days. Because the two medicines were tested in separate trials, these figures cannot tell you which works better.

Sources for this section

Nurtec ODT for episodic migraine prevention

Nurtec ODT is a 75 mg orally disintegrating small-molecule tablet sold in eight-tablet cartons. FDA approves it for prevention of episodic migraine in adults and separately for treating an attack. Confirm whether the benefit covers the prescribed quantity under the intended use.

The label lists nausea and stomach pain or indigestion among common adverse reactions in prevention. It also warns about serious allergic reactions, high blood pressure and Raynaud’s phenomenon.

Sources for this section
Explore Brain Health